Related references
Note: Only part of the references are listed.Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
Emma L. van der Ende et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
Dallas P. Veitch et al.
ALZHEIMERS & DEMENTIA (2019)
Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays
Kaj Blennow et al.
SCIENTIFIC REPORTS (2019)
Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease
Douglas Galasko et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2019)
Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease
Courtney L. Sutphen et al.
ALZHEIMERS & DEMENTIA (2018)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack et al.
ALZHEIMERS & DEMENTIA (2018)
Neurogranin as a predictor of memory and executive function decline in MCI patients
Alison Headley et al.
NEUROLOGY (2018)
Current state of Alzheimer's fluid biomarkers
Jose Luis Molinuevo et al.
ACTA NEUROPATHOLOGICA (2018)
Presynaptic Neuronal Pentraxin Receptor Organizes Excitatory and Inhibitory Synapses
Sung-Jin Lee et al.
JOURNAL OF NEUROSCIENCE (2017)
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia
Davide Chiasserini et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
NPTX2 and cognitive dysfunction in Alzheimers Disease
Mei-Fang Xiao et al.
ELIFE (2017)
Neuronal Pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer's disease spectrum
Ashley Swanson et al.
BRAIN BEHAVIOR AND IMMUNITY (2016)
Research priorities to reduce the global burden of dementia by 2025
Hirai Shah et al.
LANCET NEUROLOGY (2016)
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson et al.
LANCET NEUROLOGY (2016)
Pentraxins Coordinate Excitatory Synapse Maturation and Circuit Integration of Parvalbumin Interneurons (vol 85, pg 1257, 2015)
Kenneth A. Pelkey et al.
NEURON (2016)
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease
Rawan Tarawneh et al.
JAMA NEUROLOGY (2016)
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease
Erik Portelius et al.
BRAIN (2015)
Pentraxins Coordinate Excitatory Synapse Maturation and Circuit Integration of Parvalbumin Interneurons
Kenneth A. Pelkey et al.
NEURON (2015)
High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid
Ronald C. Hendrickson et al.
PLOS ONE (2015)
Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF
Daniel S. Spellman et al.
PROTEOMICS CLINICAL APPLICATIONS (2015)
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls
Hlin Kvartsberg et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort
Maartje I. Kester et al.
ALZHEIMERS RESEARCH & THERAPY (2015)
Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old
John L. Robinson et al.
BRAIN (2014)
Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics
Kristin R. Wildsmith et al.
MOLECULAR NEURODEGENERATION (2014)
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Jon B. Toledo et al.
ACTA NEUROPATHOLOGICA (2013)
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Michael W. Weiner et al.
Alzheimers & Dementia (2013)
Heart fatty acid binding protein and Aβ-associated Alzheimer's neurodegeneration
Rahul S. Desikan et al.
MOLECULAR NEURODEGENERATION (2013)
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
Clifford R. Jack et al.
NEUROLOGY (2013)
Obligatory Role for the Immediate Early Gene NARP in Critical Period Plasticity
Yu Gu et al.
NEURON (2013)
Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
Peder Buchhave et al.
ARCHIVES OF GENERAL PSYCHIATRY (2012)
Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
Holly D. Soares et al.
ARCHIVES OF NEUROLOGY (2012)
Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis
Rebecca Craig-Schapiro et al.
PLOS ONE (2011)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack et al.
LANCET NEUROLOGY (2010)
Narp regulates homeostatic scaling of excitatory synapses on parvalbumin-expressing interneurons
Michael C. Chang et al.
NATURE NEUROSCIENCE (2010)
mGluR1/5-Dependent long-term depression requires the regulated ectodomain cleavage of neuronal pentraxin NPR by TACE
Richard W. Cho et al.
NEURON (2008)
A century of Alzheimer's disease
Michel Goedert et al.
SCIENCE (2006)
Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity
DS Xu et al.
NEURON (2003)
Synaptically targeted Narp plays an essential role in the aggregation of AMPA receptors at excitatory synapses in cultured spinal neurons
R O'Brien et al.
JOURNAL OF NEUROSCIENCE (2002)
Share Paper
